The focus of the industry is living organisms. The highly monitored standards make it a unique concern for business leaders. These features also make the industry a natural incubator for creativity, leading to significant breakthroughs that have increased yields in agriculture, produced biofuels, and resulted in life-saving pharmaceutical products.
When it comes to strategies that generate revenue, biotech start-ups have many options. The majority choose either a technology partnership or an asset creation-and-out licensing strategy. Technology-based partnerships can produce more revenue and lower financial risk, while asset creation and outlicensing strategies are able to yield much higher returns. A increasing number of biotechs at the research phase employ a hybrid strategy that combines both strategies.
If you choose to https://genotec-frankfurt.de/comparing-biotechnologically-engineered-nutritious-supplements/ go with a product-oriented strategy can reap commercial success as long as they are able to bring their pipelines to the right level, and attract a large pharmaceutical partner or investor with deep pockets. It can be a costly proposition but making sure that you balance opportunistic methods to leverage outside resources with the right research-based decision making about homegrown projects is key.
Alternatively, the “platform” model offers an alternative path to revenue. It is less expensive than product-oriented research, but is a risky option. In this model biotechs own and develops its platform technology prior to partnering with big pharma companies to create a portfolio drug discovery projects that target specific disease areas (i.e. disease that is x within biology and y). Advinus Therapeutics, among others have adopted this strategy.